Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will …

Attempts to reduce the human immunodeficiency virus type 1 (HIV-1) reservoir and induce
antiretroviral therapy (ART)-free virologic control have largely been unsuccessful. In this …

Antiretroviral therapy controls HIV replication but does not eliminate the virus from the
infected host. The persistence of a small pool of cells harboring integrated and replication …

Clonal expansion of infected CD4+ T cells is a major mechanism of HIV-1 persistence and a
barrier to achieving a cure. Potential causes are homeostatic proliferation, effects of HIV-1 …

Despite long-term antiretroviral therapy (ART), HIV-1 persists within a reservoir of CD4+ T
cells that contribute to viral rebound if treatment is interrupted. Identifying the cellular …

The phenotypic characterization of the cells in which HIV persists during antiretroviral
therapy (ART) remains technically challenging. We developed a simple flow cytometry …

Latency reversal agents (LRAs) have proven to induce HIV-1 transcription in vivo but are
ineffective at decreasing the size of the latent reservoir in antiretroviral treated patients. The …

After initiating antiretroviral therapy (ART), a rapid decline in HIV viral load is followed by a
long period of undetectable viremia. Viral outgrowth assay suggests the reservoir continues …

The development of latency reversing agents that potently reactivate HIV without inducing
global T cell activation would benefit the field of HIV reservoir research and could pave the …

The latent reservoir is a major barrier to HIV cure. As latently infected cells cannot be
phenotyped directly, the features of the in vivo reservoir have remained elusive. Here, we …